Oncology Times
OncTimes Talk
OncTimes Talk features a variety of podcast series ranging from breaking news and oncology conference coverage to story round-ups and in-depth interviews with current experts and leaders in oncology.
Be sure to visit the podcast's website and support the creator: journals.lww.com
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
Afatinib Recommended for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations 16.02.2024 8:33
The preferred first-line treatment for patients with uncommon sensitizing mutations in tumor epidermal growth factor receptor (EGFR) should now be the tyrosine kinase inhibitor (TKI) afatinib, rather than osimertinib, according to Japanese researchers reporting the ACHILLES trial results at the ESMO Congress 2023 held in Madrid. OncTimesTalk correspondent Peter Goodwin talked with Satoru Miura,...
Adjuvant Radiotherapy No Benefit After Radical Prostatectomy 14.02.2024 15:24
Patients with high-risk prostate cancer who have been treated with radical prostatectomy gain no additional advantage and face extra toxicity if they choose to have adjuvant radiotherapy. That's according to the findings of the randomized RADICALS study, reported at the ESMO Congress 2023. These results support the use of early salvage radiotherapy for PSA failure after radical prostatectomy rathe...
Collagen-Bound Interleukin 12 Converts "Cold" Tumors Into "Hot" Ones 14.02.2024 14:51
Although immunotherapies for patients with solid tumors such as melanoma can be dramatically successful, the majority of patients are resistant and require alternative treatments. While the cytokine interleukin-12 is well known for potentiating the effect of immunotherapies, such as checkpoint blockade, it couldn't be used because of toxicity. At the 2023 AACR-NCI-EORTC International Conference...
Allogeneic Transplant for AML: Only in Patients Negative for Molecular Minimum Residual Disease 07.02.2024 15:44
The process of identifying which patients with acute myeloid leukemia (AML) can benefit from allogeneic stem cell transplantation in first complete remission (CR1) has taken a step forward thanks to analysis of the UK NCRI AML17 and AML19 studies, reported at the 65th ASH Annual Meeting and Exposition. Patients who achieved molecular residual disease (MRD) negativity in their peripheral blood we...
Antibody-Drug Conjugate Brings Success in High-Risk R/R Follicular Lymphoma 06.02.2024 22:12
With no standard-of-care treatment for patients with high-risk relapsed/refractory follicular lymphoma, promising remissions have been observed in a Phase II study reported at the 65th ASH Annual Meeting and Exposition. The antibody-drug conjugate loncastuximab tesirine in combination with rituximab brought a very high complete metabolic response rate among patients satisfying the criteria for hig...
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.